Empagliflozin is an oral treatment for type 2 diabetes mellitus (T2DM), one of the leading causes of death in the US and around the world.
INTRODUCTION
Diabetes mellitus is a major cause of mortality around the world [1] , ranked as the seventh most common cause of death in the US according to the most recent data available [2] . The actual clinical event that leads to death in people with diabetes is typically cardiovascular (CV) disease, which is thought to account for around half of deaths [1] . Recently, it has been estimated that a 60-year-old male with diabetes but without a history of CV disease (defined for this analysis as myocardial infarction [MI] or stroke) could expect to die 6 years earlier than a similar person without diabetes, while a similar male with diabetes as well as MI or stroke could expect to die about 12 years earlier [3] . About 59% of this reduced life expectancy could be attributed to death from CV causes [3] . In addition to CV disease, diabetes is associated with other serious comorbidities, notably peripheral vascular disease and microvascular complications such as retinopathy, nephropathy, and neuropathy [1] .
In type 2 diabetes mellitus (T2DM), which accounts for the vast majority of cases of diabetes, it has been known for some years that treatment to improve glycemic control can reduce the risk of microvascular complications [4, 5] . For CV complications, the benefit of treating hyperglycemia has been less cleardespite epidemiological data showing a direct relationship between increased blood glucose levels and CV disease risk [6] . Intensive glycemic control reduced the risk of MI and of all-cause mortality in newly diagnosed patients in the UK Prospective Diabetes Study (UKPDS), but only after long-term follow-up (the ''legacy'' effect) [7] . The UKPDS study began in the 1970s, before the statin era, and whether the same benefit would be seen in patients receiving today's standard of care is of course unknown. Since the UKPDS study, a number of T2DM drugs have become available, but none have conclusively shown reduced risk of CV events in high-risk patients with T2DM. The drug that probably came closest to demonstrating this was pioglitazone, which showed a 16% relative risk reduction in the secondary endpoint of all-cause mortality, non-fatal myocardial infarction, and stroke [hazard ratio (HR) 0.84,
95%
CI: 0.72-0.98; P = 0.027] [8] . Unfortunately, this study did not meet its primary endpoint, thought by many to be a dilution of a true effect by inclusion of revascularization in the primary composite.
This left the value of the secondary results uncertain and requiring confirmation in a dedicated clinical trial. Thus, based on all the available data, metformin has been recommended as first-line therapy with general principles to customize treatment targets, as well as the drug(s) used, to the needs of individual patients [9, 10] . In 2015, the wait for definitive results ended when the EMPA-REG OUTCOME study reported a lower rate of major adverse cardiovascular events (MACE), CV death, and death from any cause with the relatively new drug empagliflozin versus placebo [11] . Both were added to standard of care in patients with T2DM at high risk for CV events.
Given the history of negative or neutral results in CV outcome trials over the preceding years, EMPA-REG OUTCOME generated considerable excitement in the T2DM community. This was the first dedicated trial to show CV benefit of a glucose-lowering therapy in T2DM; subsequently, trials have reported CV benefit with liraglutide [12] and semaglutide [13] . A further trial has demonstrated reduced risk of stroke or MI with the T2DM drug pioglitazone in patients with a history of cerebrovascular disease and insulin resistance but without T2DM [14] .
Following the initial presentation of the EMPA-REG OUTCOME results, specialists around the world have been considering the results and how they might impact treatment decisions in clinical practice. Further analysis showed empagliflozin reduced the risk of hospitalization for heart failure, and this benefit was consistent in patients with and without baseline heart failure [15] . Empagliflozin was also associated with improvements in renal outcomes, including a 39% reduction in new onset or worsening of nephropathy (HR 0.61; P\0.001) [16] . There has been some speculation on whether the benefit seen with empagliflozin may have resulted, at least in part, from factors other than improvements in blood glucose control, such as a hemodynamic or volume effect [17] . This review considers the clinical trial evidence and mechanism of action of empagliflozin, before taking a closer look at the EMPA-REG OUTCOME study and how the results may influence treatment decisions, particularly in primary care practice.
METHODS
To identify publications of clinical trials for empagliflozin for this narrative review, PubMed was searched using the term ''empagliflozin'' for articles published after 2000 up to 8 August 2016. Results were reviewed to identify all phase 3 trials, including placebo-controlled and active-controlled trials, as well as secondary publications from the EMPA-REG OUTCOME study. No restrictions were placed on other study characteristics, such as number of patients, endpoint, etc. Additional pooled analyses and relevant review articles were also selected from this list. This article does not contain any new studies with human or animal subjects performed by any of the authors.
GLYCEMIC MECHANISM OF ACTION OF SGLT2 INHIBITORS
Empagliflozin is a member of a class of drugs known as sodium glucose cotransporter 2 (SGLT2) inhibitors. As their name suggests, these drugs inhibit the action of the SGLT2 protein, a glucose transporter found mainly in the proximal tubule of the kidney. SGLT2 is the transporter predominately responsible for reabsorption of glucose from the glomerular filtrate back into the circulation [18] .
All available SGLT2 inhibitors are competitive selective inhibitors of SGLT2, although there is some variation among agents in selectivity for SGLT2 over SGLT1, which is the other main glucose transporter in the kidney [19] . By inhibiting SGLT2, these drugs reduce the reabsorption of filtered glucose in the kidney, thus increasing urinary glucose excretion. The kidneys filter around 180 g of glucose every day, and without inhibition, all this glucose is reabsorbed; the majority of glucose is reabsorbed by SGLT2 and a minority by SGLT1
[20]. When SGLT2 inhibitors are used, around a third of this glucose-approximately 60 g/daywill be lost in the urine (it is thought that SGLT1 compensates to some extent for the inhibited SGLT2; hence the majority of glucose is not lost)
[21]. The actual amount of glucose excreted will also depend on factors such as the binding affinity of the specific SGLT2 inhibitor and the dose used; for example, with empagliflozin, urinary glucose excretion is about 64 g/day with empagliflozin 10 mg and 78 g/day with empagliflozin 25 mg [22] .
In addition to lowering blood glucose levels, SGLT2 inhibitors also have an effect on body weight and blood pressure (BP). The body weight effect is believed to result from lost calories, although patients most likely compensate by increasing their calorie intake, and weight loss stabilizes over time [23] .
Reduction in BP probably involves several different pathways, including osmotic diuresis, secondary effects of weight loss, and beneficial changes in arterial stiffness and vascular resistance [24] .
With any drug for T2DM, hypoglycemia is a key concern. Mild hypoglycemia can be frightening for patients, but severe hypoglycemia (usually defined as needing the assistance of another person to actively administer carbohydrate, glucagon, or other emergency interventions) can be life threatening [25] . Hypoglycemia may also be linked with other poor outcomes (e.g., the incidence of arrhythmia and possibly death in people with CV disease) [26] . Insulin and drugs that stimulate the secretion of insulin, such as sulfonylureas, are associated with increased risk of hypoglycemia [25] . However, SGLT2 inhibitors do not stimulate insulin secretion and do not tend to increase the risk of hypoglycemia, unless used together with a sulfonylurea or insulin.
EMPAGLIFLOZIN CLINICAL DATA

Blood Glucose Control
Empagliflozin is taken orally and is available in two doses: 10 and 25 mg once daily. It is rapidly absorbed, with limited metabolism, and is excreted primarily unchanged in urine and feces [27] . In patients with T2DM, empagliflozin has been studied as monotherapy and in a number of combination regimens [28] [29] [30] [31] [32] [33] [34] . Most trials have compared empagliflozin with placebo, but a head-to-head study with glimepiride has been reported [29] , and one placebo-controlled trial also included a sitagliptin arm as an active comparator [28] . Initial combinations with metformin [35] and fixed-dose combinations with linagliptin have been studied [36, 37] . In addition, empagliflozin has been studied in specific patient groups, namely those with hypertension or renal impairment, as well as the study in patients at high CV risk (EMPA-REG OUTCOME) [11, 38, 39] . Phase 3 studies for empagliflozin are summarized in Table 1 .
In these studies, empagliflozin treatment gave clinically significant reductions in glycated hemoglobin (HbA1c) compared with placebo [28, [30] [31] [32] and similar reductions to glimepiride [29] and sitagliptin [28] . In the head-to-head study of empagliflozin 25 mg versus glimepiride 1-4 mg (both as add-on to stable metformin), similar changes were seen in the two groups (Fig. 1a) [29]. However, 24% of the glimepiride group had a hypoglycemic adverse event (AE) compared with 2% of the empagliflozin 25 mg group, and the glimepiride group had an increase in body weight (mean 1.6 kg) compared with a weight loss in the empagliflozin group (mean -3.2 kg) [29] .
In a 24-week study of treatment-naïve patients with screening HbA1c 7.0-10.0%, empagliflozin also gave similar reductions in HbA1c to the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin (Fig. 1b) [28] . However, in the subgroup of patients with baseline HbA1c C8.5%, empagliflozin at either dose gave larger HbA1c reductions than sitagliptin 100 mg, whereas in patients with baseline HbA1c \8.5%, reductions remained similar for the empagliflozin and sitagliptin groups (Fig. 1b) [28] . A larger reduction in patients with higher baseline HbA1c values is expected across drug figure; in this study, patients were also randomized to placebo, but only comparisons with sitagliptin are shown for clarity. When all patients were analyzed, reductions were similar for empagliflozin and sitagliptin (mean difference for empagliflozin 10 mg vs. sitagliptin 100 mg: 0.0%, 95% CI: -0.15 to 0.14; P = 0.9697; mean difference for empagliflozin 25 mg vs. sitagliptin 100 mg: -0.12, 95% CI: -0.26 to 0.03; P = 0.1060). In the subgroup of patients with HbA1c C8.5%, mean reductions with both empagliflozin doses were significantly greater than with sitagliptin (empagliflozin 10 mg vs. sitagliptin 100 mg: P = 0.008; empagliflozin 25 mg vs. sitagliptin 100 mg: P = 0.012) [28] . Empagliflozin has also been associated with modest reductions in systolic and diastolic blood pressure (SBP/DBP). In a pooled analysis of four 24-week studies (1652 patients on empagliflozin 10 or 25 mg, 825 on placebo), the adjusted mean difference for the pooled empagliflozin groups versus placebo in change from baseline in SBP at week 24 was -3.6 mmHg (95% CI: -4.5 to -2.7; P\0.001) and in DBP was -1.3 mmHg (95% CI: -1.9 to -0.8; P\0.001) [47] . The results are in line with those of the other available SGLT2 inhibitors [24] . For fractures, a potential increased risk has been reported for canagliflozin in one long-term trial, although pooled analysis of eight trials showed a similar incidence of fracture with canagliflozin and control arms [52] . The cause is unclear, and various mechanisms have been suggested: effects on phosphorus metabolism, decreases in bone mineral density following weight loss, or possibly an increased risk of falls due to the volume effects of canagliflozin [52] .
Although increased fracture risk has not been observed in available pooled analyses for empagliflozin [48] or dapagliflozin [53] , the FDA is continuing to evaluate the risk with all available SGLT2 inhibitors [54] .
A more recent safety question with canagliflozin has been increased risk of lower limb amputations, mostly affecting the toes. At the time of writing, this has only been seen with canagliflozin, but naturally there will be concern that this may be a class effect [55] , and the European Medicines Agency is considering data on all drugs in the class [56] . Details are not yet available, but the FDA has reported an increase in leg and foot amputations in the interim results of a clinical trial, with most events affecting the toes [55] . While the FDA investigates whether this is a true signal or a chance finding, no change in clinical practice is recommended for canagliflozin. Patients should be monitored for any new pain or tenderness, sores or ulcers, or infections in their feet or legs [55] , and this seems reasonable advice to follow with empagliflozin and dapagliflozin also.
Indeed, it is reasonable to advise all patients with diabetes to examine their feet and have their practitioner do so as well.
EMPA-REG OUTCOME STUDY
Unlike the trials discussed above, EMPA-REG OUTCOME was designed to study CV events rather than look at measures of glucose control (HbA1c). The trial recruited patients who had T2DM and established CV disease (including peripheral arterial disease), provided they had not had acute coronary syndrome, stroke, or a transient ischemic attack within the 2 months before the study [11] . Patients with established CV disease are of course at increased risk of events, powering the study to demonstrate CV safety while also providing the potential to demonstrate CV benefit.
To be included in the study, patients had to have HbA1c of 7-9% if they were not on glucose-lowering therapy or 7-10% if they were on glucose-lowering therapy. Patients were also required to have eGFR C30 ml/min/ Approximately 90% were on antiplatelet therapy, mainly aspirin. Thus, by most standards these patients were well managed and received incremental benefit on top of the therapy they were already receiving.
The primary outcome measure was time to first occurrence of CV death, non-fatal MI, or non-fatal stroke (3-point MACE), with events independently adjudicated. The study design was event-driven, targeting at least 691 outcome events to provide 90% power to assess whether empagliflozin was non-inferior to placebo (i.e., CV safety) and 80% power to assess superiority (i.e., CV benefit) [57] . For the primary analysis, the two empagliflozin dose groups were to be pooled [57] .
Patients were recruited between September 2010 and April 2013; 7020 patients were enrolled and treated at 590 sites in 42 countries [11] . The median treatment time was 2.6 years, and there were 772 primary outcome events overall. As shown in Fig. 2a for non-inferiority, P = 0.08 for superiority).
These results were exciting, but even more intriguing were individual components of the primary outcome: the biggest reduction was seen in CV mortality. As shown in Fig. 2b (Fig. 3) [11]. It is not possible to directly compare the results with those of previous trials, but it is worth considering in context of the numbers needed to treat with statins and antihypertensive drugs [59, 60] and bearing in mind that the reduction with Fig. 3 Number of patients who would need to be treated to prevent one death (from any cause) across different landmark trials in patients with high CV risk. The studies reported were separate trials and not head-to-head comparisons. 4S: about 5% of patients had diabetes (not specified T1DM or T2DM) [60] . All patients had a history of acute angina or MI (or both). Median follow-up was 5.4 years. The incidence of all-cause mortality during the trial was 11.5% in the placebo group and 8.2% in the simvastatin group. HOPE: all patients were aged C55 years, about 88% had a history of CV disease (8162/9297), and the remainder had diabetes plus at least 1 additional CV risk factor. Of the total group, 38% had diabetes (not specified T1DM or T2DM) [59] . The incidence of all-cause mortality during the trial was 10.4% in the ramipril group and 12.2% in the placebo group. EMPA-REG OUTCOME: All patients had T2DM, and all had a history of CV disease [11] . The incidence of all-cause mortality during the trial was 8.3% in the placebo group and 5.7% in the empagliflozin group (empagliflozin 10 and 25 mg combined). LEADER: All patients had T2DM, 81.3% had a history of CV disease, and the remainder had high CV risk (aged[60 years and C1 other CV risk factor in addition to T2DM) [12] . The incidence of all-cause mortality during the trial was 9.6% in the placebo group and 8.2% in the liraglutide group. The number of patients on all anti-HTN therapy is given because the overall proportion on either ACEIs or ARBs was not reported. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CV cardiovascular, HTN hypertension, MI myocardial infarction, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus empagliflozin was seen on top of standard of care treatments. In the LEADER study, the number needed to treat with liraglutide for 3.5 years to prevent one all-cause death was 98 (Fig. 3) [12] . The reduction in the risk of hospitalization for heart failure was also striking, with subgroup analysis showing consistent results in patients with or without heart failure at baseline [15] .
Patients with diabetes and heart failure have a particularly poor prognosis [61] ; thus, while the results seen with empagliflozin are still to be confirmed by independent studies, they are very promising. Even in patients without diabetes, heart failure is a challenging condition to treat, and it has been reported that empagliflozin will be studied in patients with heart failure, both with and without T2DM [62] . During the trial, renal outcomes were also In the EMPA-REG OUTCOME study overall, the safety profile was much as expected from the clinical trial program, notably increased risk of genital mycotic infections. Confirmed hypoglycemic events, with plasma glucose \70 mg/dl (3.9 mmol/l) or requiring assistance, were reported in similar proportions of the groups, suggesting no increased risk. Events requiring assistance were seen in 1.5% of the placebo group, 1.4% of the empagliflozin 10 mg group, and 1.3% of the empagliflozin 25 mg group. Of the other AEs of interest discussed above, there appeared to be no increased risk of ketoacidosis or of bone fracture; amputations were not reported.
Also as expected from the clinical trial program, empagliflozin was associated with modest reductions in weight and BP, as well as HbA1c. After 12 weeks (the period when background therapies were held stable), mean placebo-corrected HbA1c reductions were -0.60% in the 25 mg group, but more patients in the placebo group received additional glucose-lowering drugs during the trial, and the difference between groups fell (although remaining statistically significant).
Together with the early onset of benefit in CV mortality and the lack of improvement in MI, the small difference in HbA1c levels between the groups suggests an alternative mechanism for the benefit seen with empagliflozin. Suggested mechanisms include the possibility of a diuretic effect causing a decrease in preload and afterload (albeit diuretic drugs have not shown similar results in clinical trials) and an effect on sympathetic tone [63] . Other alternatives include an increase in glucagon, leading to inotropic and antiarrhythmic effects [64] , or an increase in ketone production with empagliflozin leading to preferential utilization of ketones by both the heart and kidneys in turn resulting in decreased workload and improved cardiac and renal function [65] . During the trial, small increases were seen in levels of low-and high-density cholesterol, and it is possible that these may have contributed even though the patients were in general well controlled on statins. Indeed, it seems likely that several mechanisms may be working together to cause the overall benefit. Experts continue to debate the possible mechanism, and research to define it may well go on for many years to come. Nevertheless, based on opinion surveys, it appears the results have already had an impact on clinical practice [66] . This group lists SGLT2 inhibitors along with five other options to use in combination with metformin, although given that there were no available data on CV outcomes with SGLT2
PLACE OF SGLT2 INHIBITORS IN CLINICAL GUIDELINES
inhibitors at the time this position statement was written, further updates may be expected, perhaps also with the results of the LEADER trial.
The ADA 2016 Standards of Care in Diabetes discuss the EMPA-REG OUTCOME study results, noting one of the advantages of SGLT2
inhibitors as a class is the association of empagliflozin with a lower CV disease event rate and mortality in patients with CV disease. However, these guidelines continue to list SGLT2
inhibitors among various options, with the recommendation to select therapies based on individual patient needs [25] . The AACE/ACE consensus statement on management of T2DM is updated annually, and the 2016 update included discussion of EMPA-REG OUTCOME [10] . Again, this group continues to list SGLT2 inhibitors among various agents, although they raised the class in the hierarchy of alternative options.
Why has neither group rushed to recommend empagliflozin as first-line treatment, given the excitement around the results? This is clarified in an interim guideline update by the Canadian Diabetes Association, recently issued in response to the EMPA-REG OUTCOME results [67] . They point out that the patients in EMPA-REG OUTCOME not only had a history of CV disease, but fewer than 2% of patients were drug-naïve, and patients typically [68] . Metformin remains the first-line option, but based on the results of the EMPA-REG OUTCOME study, the ESC recommends that an SGLT2 inhibitor should be considered very early in the course of diabetes management in patients with T2DM and existing CV disease [68] . The ESC also updated their guidelines on heart failure to include empagliflozin to prevent or delay the onset of heart failure in patients with T2DM [69] . As with general CV disease prevention recommendations, they continue to recommend metformin as first-line therapy for glycemic control and also point out that intensification of glucose control with agents other than empagliflozin does not reduce the risk of heart failure [69] .
Unfortunately, EMPA-REG OUTCOME was not designed to provide information on primary prevention, and such a study is unlikely to be conducted. For the other SGLT2 inhibitors, although the CANVAS and DECLARE trials have included patients both with and without a history of CV disease, in those without a history, high CV risk due to other factors was required [70, 71] , and the VERTIS CV study of ertugliflozin includes only patients with a history of atherosclerotic disease [72] . Therefore, at present, the guidelines make sense in the context of considering a history of CV disease as a patient characteristic to guide decisions for individual patients, with empagliflozin, on top of standard of care, considered in such cases. To some extent, treatment decisions will depend on labeling updates for empagliflozin and whether a new indication is likely. The FDA is reviewing the CV risk reduction data from EMPA-REG OUTCOME and a decision is expected in 2016 [73] .
CONCLUSION
So what is the best approach for T2DM patients with a relatively low short-term risk of CV events? Continuing clinical experience is still required, since these are relatively new drugs.
None of the CV outcomes trials with SGLT2 inhibitors are likely to inform the use of these agents in such patients. Rather, other considerations, such as impact on weight and SBP as well as glycemic-lowering potential, weighed against typical AEs of genital mycotic infections, will guide the use of empagliflozin for these patients. However, in patients with T2DM and established CVD, based on the EMPA-REG OUTCOME results, empagliflozin is a reasonable option.
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